| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 From Neurotech USA, Lincoln, Rhode Island; the 2 University of Pennsylvania Medical Center, Philadelphia, Pennsylvania; the 3 Rhode Island Hospital, Providence, Rhode Island; and the 4 James A. Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, New York.
PURPOSE. The objective of the present study was to evaluate the therapeutic efficacy of ciliary neurotrophic factor (CNTF) delivered through encapsulated cells directly into the vitreous of the eye in an rcd1 canine model of retinitis pigmentosa. The dose–range effect of the treatment was also investigated.
METHODS. Polymer membrane capsules (1.0 cm in length and 1.0 mm in diameter) were loaded with mammalian cells that were genetically engineered to secrete CNTF. The cell-containing capsules were then surgically implanted into the vitreous of one eye of rcd1 dogs at 7 weeks of age, when retinal degeneration is in progress but not complete. The contralateral eyes were not treated. The capsules remained in the eyes for 7 weeks. At the end of the studies, the capsules were explanted, and CNTF output and cell viability were evaluated. The eyes were processed for histologic evaluation.
RESULTS. In each animal, the number of rows of photoreceptor nuclei in the outer nuclear layer (ONL) was significantly higher in the eye that received a CNTF-secreting implant than in the untreated contralateral eye. No adverse effects were observed on the retina in the treated eyes. The explanted capsules produced a low level of CNTF. The cells in the capsules remained viable and densely distributed throughout.
CONCLUSIONS. CNTF delivered through encapsulated cells directly into the vitreous of the eye protects photoreceptors in the PDE6B-deficient rcd1 canine model. Furthermore, sparing of photoreceptors appeared dose-dependent with minimum protection observed at CNTF doses of 0.2 to 1.0 ng/d. Incrementally greater protection was achieved at higher doses. The surgically implanted, cell-containing capsules were well tolerated, and the cells within the capsule remained viable for the 7-week implantation interval. These results suggest that encapsulated cell therapy may provide a safe and effective strategy for treating retinal disorders in humans.
This article has been cited by other articles:
|
|
 |
|
  T. L. Kent, I. V. Glybina, G. W. Abrams, and R. Iezzi Chronic Intravitreous Infusion of Ciliary Neurotrophic Factor Modulates Electrical Retinal Stimulation Thresholds in the RCS Rat Invest. Ophthalmol. Vis. Sci., January 1, 2008; 49(1): 372 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. McGill, G. T. Prusky, R. M. Douglas, D. Yasumura, M. T. Matthes, G. Nune, K. Donohue-Rolfe, H. Yang, D. Niculescu, W. W. Hauswirth, et al. Intraocular CNTF Reduces Vision in Normal Rats in a Dose-Dependent Manner Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5756 - 5766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Rhee, A. Ruiz, J. L. Duncan, W. W. Hauswirth, M. M. LaVail, D. Bok, and X.-J. Yang Molecular and Cellular Alterations Induced by Sustained Expression of Ciliary Neurotrophic Factor in a Mouse Model of Retinitis Pigmentosa Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 1389 - 1400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. DeMarco Jr, G. L. Yarbrough, C. W. Yee, G. Y. McLean, B. T. Sagdullaev, S. L. Ball, and M. A. McCall Stimulation via a Subretinally Placed Prosthetic Elicits Central Activity and Induces a Trophic Effect on Visual Responses Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 916 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Paskowitz, K. M. Donohue-Rolfe, H. Yang, D. Yasumura, M. T. Matthes, K. Hosseini, C. M. Graybeal, G. Nune, M. A. Zarbin, M. M. LaVail, et al. Neurotrophic Factors Minimize the Retinal Toxicity of Verteporfin Photodynamic Therapy Invest. Ophthalmol. Vis. Sci., January 1, 2007; 48(1): 430 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Wen, Y. Song, S. Kjellstrom, A. Tanikawa, Y. Liu, Y. Li, L. Zhao, R. A. Bush, A. M. Laties, and P. A. Sieving Regulation of Rod Phototransduction Machinery by Ciliary Neurotrophic Factor J. Neurosci., December 27, 2006; 26(52): 13523 - 13530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Samardzija, A. Wenzel, S. Aufenberg, M. Thiersch, C. Reme, and C. Grimm Differential role of Jak-STAT signaling in retinal degenerations FASEB J, November 1, 2006; 20(13): 2411 - 2413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Gilger, J. H. Salmon, D. A. Wilkie, L. P. J. Cruysberg, J. Kim, M. Hayat, H. Kim, S. Kim, P. Yuan, S. S. Lee, et al. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2596 - 2605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Sieving, R. C. Caruso, W. Tao, H. R. Coleman, D. J. S. Thompson, K. R. Fullmer, and R. A. Bush Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants PNAS, March 7, 2006; 103(10): 3896 - 3901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yzer, B. P. Leroy, E. De Baere, T. J. de Ravel, M. N. Zonneveld, K. Voesenek, U. Kellner, J. P. M. Ciriano, J.-T. H. N. de Faber, K. Rohrschneider, et al. Microarray-based mutation detection and phenotypic characterization of patients with leber congenital amaurosis. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 1167 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Kukekova, J. Nelson, R. W. Kuchtey, J. K. Lowe, J. L. Johnson, E. A. Ostrander, G. D. Aguirre, and G. M. Acland Linkage Mapping of Canine Rod Cone Dysplasia Type 2 (rcd2) to CFA7, the Canine Orthologue of Human 1q32. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 1210 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Pardue, M. J. Phillips, H. Yin, B. D. Sippy, S. Webb-Wood, A. Y. Chow, and S. L. Ball Neuroprotective Effect of Subretinal Implants in the RCS Rat Invest. Ophthalmol. Vis. Sci., February 1, 2005; 46(2): 674 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Jacobson, A. Sumaroka, T. S. Aleman, A. V. Cideciyan, S. B. Schwartz, A. J. Roman, R. R. McInnes, V. C. Sheffield, E. M. Stone, A. Swaroop, et al. Nuclear receptor NR2E3 gene mutations distort human retinal laminar architecture and cause an unusual degeneration Hum. Mol. Genet., September 1, 2004; 13(17): 1893 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Bush, B. Lei, W. Tao, D. Raz, C.-C. Chan, T. A. Cox, M. Santos-Muffley, and P. A. Sieving Encapsulated Cell-Based Intraocular Delivery of Ciliary Neurotrophic Factor in Normal Rabbit: Dose-Dependent Effects on ERG and Retinal Histology Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2420 - 2430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Zeiss and E. A. Johnson Proliferation of Microglia, but not Photoreceptors, in the Outer Nuclear Layer of the rd-1 Mouse Invest. Ophthalmol. Vis. Sci., March 1, 2004; 45(3): 971 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Song, L. Zhao, W. Tao, A. M. Laties, Z. Luo, and R. Wen Photoreceptor Protection by Cardiotrophin-1 in Transgenic Rats with the Rhodopsin Mutation S334ter Invest. Ophthalmol. Vis. Sci., September 1, 2003; 44(9): 4069 - 4075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Beltran, Q. Zhang, J. W. Kijas, D. Gu, H. Rohrer, J. A. Jordan, and G. D. Aguirre Cloning, Mapping, and Retinal Expression of the Canine Ciliary Neurotrophic Factor Receptor {alpha} (CNTFR{alpha}) Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3642 - 3649. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
